EU Critical Medicines Act to Favor Local Production
A new EU law will use procurement preferences and financial aid to incentivize local production of critical medicines, shifting the market to favor supply-chain resilience over lowest cost.
The EU has reached a provisional political agreement on its Critical Medicines Act, a significant legislative effort to secure the bloc's supply of essential pharmaceuticals. The Act introduces a "stick and carrot" approach to incentivize onshoring. Contracting authorities in public procurement procedures will be required to implement resilience-related criteria that establish a preference for EU-manufactured critical medicines. For non-EU producers, this could dilute the appeal of cheaper generics and may necessitate establishing EU production facilities or partnerships. To further support this shift, the Act allows member states and the EU to designate certain projects as "strategic," granting them access to fast-track permits, streamlined administrative processes, and direct financial support. Pharmaceutical manufacturers and their investors should now assess their supply chains and EU manufacturing capacity, as the legislation signals a structural shift away from lowest-price models toward rewarding local production and supply-chain security. The final text is expected by late 2026 or early 2027.